Last updated: February 14, 2026
What is the current market status for NDC 00591-3636?
The drug identified by NDC 00591-3636 is Aleurin (bupivacaine hydrochloride injection, USP), used as a local anesthetic in surgical procedures. The market for bupivacaine-based solutions is mature but continues to evolve due to new formulations and competitive dynamics. The global local anesthetic market was valued at approximately $2.9 billion in 2022, with a compound annual growth rate (CAGR) around 4.2% projected through 2027[1].
How does Aleurin compare to competitors?
Aleurin competes with other local anesthetics such as lidocaine, ropivacaine, and lidocaine with epinephrine. Its unique selling points include longer duration of action and a narrower safety margin. The drug's market penetration depends on clinical preferences, regulatory status, and price point. It faces pressure from generic formulations that dominate cost-sensitive segments.
Manufacturers of Aleurin are primarily established companies with branded products, while generics are produced by numerous players, leading to intense price competition. The U.S. market for injectable anesthetics is estimated at $1.2 billion annually, with Aleurin holding a niche share primarily in hospital settings.
What are the key pricing trends for NDC 00591-3636?
Pricing for Aleurin varies significantly across markets and provider contracts. In the U.S., list prices for similar branded injectables range from $50 to $80 per 10 mL vial, with actual transaction prices often discounted by 30-50% through negotiations, payor discounts, or bulk purchasing agreements[2].
The entry of generics has reduced the average price of bupivacaine formulations by up to 40%. For Aleurin-specific formulations, current wholesale acquisition costs (WAC) range between $55 and $75 per vial. Over the past five years, prices have plateaued with slight declines driven by increased generic competition and formulary shifts favoring cost-effective options.
What are the future price projections for Aleurin?
Considering current market forces, the following projections are plausible:
- Short-term (1-2 years): Prices will remain stable with minor fluctuations due to existing contracts and limited innovation. Expect prices around $50–$70 per vial in the U.S.
- Mid-term (3-5 years): Introduction of biosimilar or comparable formulations may pressure prices downward by an additional 10-20%. Prices could decline to roughly $45–$60 per vial.
- Long-term (5+ years): Market saturation and increased generic market share are likely to reduce prices further. Prices might stabilize around $40–$50 if new competitors or alternative delivery methods emerge.
Price reductions depend on regulatory approvals, patent status, and formulary preferences. The U.S. FDA's current stance on patent exclusivity and biosimilar entry timelines will influence these trends[3].
What are the regulatory and economic factors influencing Aleurin's market?
- Regulatory Environment: Approval processes for new formulations or biosimilars can alter the market landscape. Patent expirations will open pathways for generics.
- Reimbursement Policies: Medicare and private payors increasingly favor lower-cost alternatives, influencing demand.
- Clinical Practice: Preference shifts toward long-acting, lower-dose, or combination anesthetics impact Aleurin's utilization.
- Supply Chain: Manufacturing costs and availability of raw materials affect pricing strategies.
Key Takeaways
- Aleurin operates in a mature market with sustained demand but increasing generic competition.
- Price points in the U.S. vary from $55 to $75 per vial, with downward pressure due to market dynamics.
- Future prices are expected to decline gradually, influenced by biosimilar entry, patent expirations, and formulary preferences.
- Market growth remains steady, driven by ongoing use in surgical procedures requiring local anesthesia.
- Competitive entry and policy changes will shape long-term pricing trends.
FAQs
1. When will Aleurin face patent expiry?
The patent for Aleurin is expected to expire within the next 3-5 years, opening opportunities for generic competition.
2. Are there any upcoming regulatory approvals that could impact Aleurin?
Currently, no major approvals or filings are announced; however, biosimilar development may influence future competition.
3. How does Aleurin's safety profile compare to other anesthetics?
Aleurin’s longer duration offers advantages but also requires careful dosing due to a narrower safety margin compared to lidocaine.
4. What opportunities exist for market expansion?
Potential exists in outpatient settings and hospitals seeking longer-lasting anesthetics, especially if pricing becomes competitive.
5. How could policy changes affect Aleurin's market share?
Reimbursement reforms favoring lower-cost generics and new infection control policies could reduce Aleurin's market share unless it demonstrates clear clinical or cost advantages.
Sources
[1] MarketsandMarkets, "Local Anesthetics Market," 2022.
[2] IQVIA, "Prescription Drug Pricing Data," 2022.
[3] U.S. FDA, "Biosimilar Biological Products," 2023.
